Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

(2014) RS Finn et al.   CANCER RESEARCH

Successful Treatment of Animal Models of Rheumatoid Arthritis with Small-Molecule Cyclin-Dependent Kinase Inhibitors

(2014) C. Sekine et al.   JOURNAL OF IMMUNOLOGY

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Genetics of rheumatoid arthritis contributes to biology and drug discovery

(2013) Yukinori Okada et al.   NATURE

Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study

(2013) Anne C. Bay-Jensen et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment

(2012) P. Emery   RHEUMATOLOGY

Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study

(2012) M. Tada et al.   RHEUMATOLOGY

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire

(2011) B. Haraoui et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

(2011) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Development of Novel Combination Therapies

(2011) Janet Woodcock et al.   NEW ENGLAND JOURNAL OF MEDICINE

State-of-the-art: rheumatoid arthritis

(2010) I. B. McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

PADI4 polymorphism predisposes male smokers to rheumatoid arthritis

(2010) Y. Kochi et al.   ANNALS OF THE RHEUMATIC DISEASES

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

(2010) C. Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

(2010) L. Campbell et al.   RHEUMATOLOGY

Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: All alleles are important

(2009) Emeli Lundström et al.   ARTHRITIS AND RHEUMATISM

Are new agents needed to treat RA?

(2009) Peter E. Lipsky   Nature Reviews Rheumatology

Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells

(2008) Clare A. Notley et al.   JOURNAL OF EXPERIMENTAL MEDICINE